Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…
The rapidly shifting therapeutic landscape for HER2-negative metastatic breast cancer (MBC) challenges clinicians to stay up-to-date on emerging clinical trial data, as well as recommendations on therapy selection and sequencing. Unfamiliarity with antibody-drug conjugate (ADC) treatment…
Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody directed against a tumor-associated antigen. Conjugation fundamentally alters tissue…
Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians…
The therapeutic landscape for HER2-neg metastatic breast cancer (HER2-neg MBC) is rapidly changing with the addition of antibody drug-conjugate (ADC) therapies. As a result, clinicians are not confident or knowledgeable in applying emerging clinical data to…
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively…
Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present…
In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers…
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…